Quote of the Day: Lucentis vs. Avastin

| Mon Nov. 8, 2010 10:09 AM PST

I love this News of the Weird summary of this New York Times article:

Treatments for Age-Related Macular Degeneration: Lucentis ($2,000 an injection) or the equally effective Avastin (off-label: $50). Problems: (a) Lucentis thus costs Medicare (i.e., you) a bargeload of money. (b) Both drugs are made by the same company. (c) That company, somehow, for some odd reason, prefers that patients use Lucentis and therefore offers a "promotion program" (i.e., bribes) for doctors to prescribe it. (Bonus: The bribes are legal.)

Stay classy, pharmaceutical industry!

Get Mother Jones by Email - Free. Like what you're reading? Get the best of MoJo three times a week.